Physician profile
Barbara A Obrien
NPI 1437211794
$1,101.23
in general payments reported to CMS, 2019-2025
19 companies · $617 in 2025
The $617 reported for 2025 was more than what 78% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $44.64 · 2024: $108 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $361.78 | 2019-2025 | |
| Abbvie INC. | $189.27 | 2019-2025 | |
| Novo Nordisk INC | $96.85 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.61 | 2019-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $52.36 | 2019-2020 | |
| Abbott Laboratories | $41.32 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $39.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $34.36 | 2019-2024 | Bexsero, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.41 | 2024-2025 | Farxiga, Airsupra |
| Shire North American Group INC | $29.29 | 2019 | |
| Globus Medical, INC. | $27.14 | 2025 | Senza |
| Janssen Pharmaceuticals, INC | $20.42 | 2024 | Spravato |
| Boston Scientific Corporation | $16.90 | 2019 | |
| Lilly USA, LLC | $15.84 | 2025 | Zepbound, Mounjaro |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.54 | 2019 | |
| Amarin Pharma, INC. | $14.26 | 2019 | |
| Genentech USA, INC. | $12.68 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.